Dr Elizabeth Jarman: key facts
- Kind of voice
- Academic
- Role
- noncommunicable diseases technical advisor, MSF Access
- Quoted on
- Diabetes
- Tracked press citations
- 2
- Most recently quoted
- 30 Sept 2026
“Novo Nordisk's discontinuation of human insulin pens and older and more affordable analogue insulin pens, such as Lemevir, for commercial reasons is yet another unacceptable example of pharmaceutical corporations putting profits before people's health.”
What Dr Elizabeth Jarman has said
“The prevalence of diabetes is rapidly increasing around the world, but access to treatment is not improving at the same rate, especially in low- and middle-income countries where modern, more efficacious, and person-preferred treatments like analogue insulin pens are unaffordable or unavailable. By introducing analogue insulin pens to its Social Health Authority benefits package, Kenya would be leading the charge towards upending the global double standard in diabetes care and ensuring that people with diabetes have more equitable access to care.”
noncommunicable diseases technical advisor, MSF Access · Diabetes · 30 Sept 2026 · MSF calls for inclusion of analogue insulin pens to the Kenyan Social Health Authority benefits package ↗
Where Dr Elizabeth Jarman has been quoted
- MSF responds to Novo Nordisk’s discontinuation of key insulin products in EU/EEAmsfaccess.org · 30 Sept 2026
- MSF calls for inclusion of analogue insulin pens to the Kenyan Social Health Authority benefits packagemsfaccess.org · 30 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.